Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.
Lancet Child Adolesc Health
; 2(1): 25-34, 2018 01.
Article
in En
| MEDLINE
| ID: mdl-29376112
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prednisone
/
Immunoglobulins, Intravenous
/
Opsoclonus-Myoclonus Syndrome
/
Anti-Inflammatory Agents
/
Neuroblastoma
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Language:
En
Journal:
Lancet Child Adolesc Health
Year:
2018
Type:
Article